Sign inCreate account

Report workspace tools

NCT04170283ACTIVE_NOT_RECRUITINGanonymous

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Sponsor

Source record

BeiGene

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

B-cell Malignancies

Indication / condition

AI-normalized

B-cell Malignancies

Intervention

Source record

Zanubrutinib, Tislelizumab

Source & freshness

Source record

NCT ID

NCT04170283

Original source

ClinicalTrials.gov

Source last updated

Oct 21, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04170283

Title

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Sponsor

BeiGene

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Condition raw

B-cell Malignancies

Condition normalized

B-cell Malignancies

Modality raw

B-cell Malignancies

Modality normalized

monoclonal antibody

Target raw

B-cell Malignancies

Target normalized

B-cell Malignancies

Interventions

Zanubrutinib, Tislelizumab

Public preview

Source record

This long-term extension study evaluates the safety and efficacy of zanubrutinib (BGB-3111) in patients with B-cell malignancies who have previously participated in a parent study. The study aims to provide insights into the long-term effects and potential benefits of continued treatment with zanubrutinib, either alone or in combination with Tislelizumab.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04170283

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Sponsor

BeiGene

Executive brief

Investment-Ready Snapshot

This long-term extension study evaluates the safety and efficacy of zanubrutinib (BGB-3111) in patients with B-cell malignancies who have previously participated in a parent study. The study aims to provide insights into the long-term effects and potential benefits of continued treatment with zanubrutinib, either alone or in combination with Tislelizumab.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 21, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04170283

Indication

B-cell Malignancies

Modality

monoclonal antibody

Target

B-cell Malignancies

Intervention

Zanubrutinib, Tislelizumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.